Results 11 to 20 of about 28,496 (220)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms

open access: yeseJHaem, 2022
This report highlights the value of flow cytometry analysis, particularly in the setting of myeloproliferative neoplasms showing features of progression, as neoplastic plasmacytoid dendritic cell (PDC) proliferations may be present, representing either a
Siba El Hussein   +11 more
doaj   +1 more source

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values

open access: yesHaematologica, 2019
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV),
Richard T. Silver, Spencer Krichevsky
doaj   +1 more source

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation

open access: yesSAGE Open Medical Case Reports, 2021
The entity myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome is characterized by the coexistence of both myeloproliferative and myelodysplastic features in the bone marrow.
Anette Lodvir Hemsing   +4 more
doaj   +1 more source

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate

open access: yesHaematologica, 2014
Clinical significance of the JAK2V617F mutation in patients with a myeloproliferative neoplasm has been the target of intensive research in recent years. However, there is considerably uncertainty about prognosis in JAK2V617F positive individuals without
Camilla Nielsen   +4 more
doaj   +1 more source

Aetiology of Myeloproliferative Neoplasms [PDF]

open access: yesCancers, 2020
Myeloproliferative neoplasms (MPNs) have estimated annual incidence rates for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis of 0.84, 1.03, and 0.47 per 100,000. Prevalence is much higher, particularly for PV and ET, as mortality rates are relatively low.
Mary Frances McMullin   +1 more
openaire   +4 more sources

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients

open access: yesHaematologica, 2011
Within a cohort of 1,915 consecutive patients with myeloproliferative neoplasm followed for a median time of 5.2 years (range 0–33.3), we investigated the occurrence of lymphoid neoplasm with the aim of defining this risk and to investigate the role of ...
Elisa Rumi   +9 more
doaj   +1 more source

Extracranial carotid artery aneurysm with myeloproliferative neoplastic cell invasion

open access: yesJournal of Vascular Surgery Cases and Innovative Techniques, 2020
The major causes of rare extracranial carotid artery aneurysms are arteriosclerosis, trauma, and radiation therapy. Here, we describe a patient with an extracranial carotid artery aneurysm caused by a myeloproliferative neoplasm.
Shotaro Ogawa, MD   +2 more
doaj   +1 more source

IL-4 Serum Level Estimation in Myeloproliferative Neoplasm Patients

open access: yesمجلة مركز بحوث التقنيات الاحيائية, 2022
Back Ground: Myeloproliferative neoplasm (MPN) is a long-term blood disease that has an excess production of mature hematopoietic pluripotent stem cells in the bone marrow. In the early fifties, W.
Ahmed Rushdi Abdullah
doaj   +1 more source

Myeloproliferative Neoplasms [PDF]

open access: yesJAMA Oncology, 2015
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are ...
Ayalew, Tefferi, Animesh, Pardanani
openaire   +2 more sources

Genetics of Myeloproliferative Neoplasms

open access: yesHematology/Oncology Clinics of North America, 2021
Myeloproliferative neoplasms are hematopoietic stem cell disorders based on somatic mutations in JAK2, calreticulin, or MPL activating JAK-STAT signaling. Modern sequencing efforts have revealed the genomic landscape of myeloproliferative neoplasms with additional genetic alterations mainly in epigenetic modifiers and splicing factors.
Jakub, Szybinski, Sara C, Meyer
openaire   +2 more sources

Home - About - Disclaimer - Privacy